IL150710A0 - Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation - Google Patents

Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation

Info

Publication number
IL150710A0
IL150710A0 IL15071001A IL15071001A IL150710A0 IL 150710 A0 IL150710 A0 IL 150710A0 IL 15071001 A IL15071001 A IL 15071001A IL 15071001 A IL15071001 A IL 15071001A IL 150710 A0 IL150710 A0 IL 150710A0
Authority
IL
Israel
Prior art keywords
receptor antagonist
smoking cessation
cannabinoid receptor
preparing medicines
central cannabinoid
Prior art date
Application number
IL15071001A
Other languages
English (en)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of IL150710A0 publication Critical patent/IL150710A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15071001A 2000-02-09 2001-02-07 Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation IL150710A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (1)

Publication Number Publication Date
IL150710A0 true IL150710A0 (en) 2003-02-12

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15071001A IL150710A0 (en) 2000-02-09 2001-02-07 Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation

Country Status (32)

Country Link
US (2) US6930122B2 (de)
EP (1) EP1257275B1 (de)
JP (2) JP2003522145A (de)
CN (1) CN1250220C (de)
AR (1) AR028505A1 (de)
AT (1) ATE292467T1 (de)
AU (1) AU781827B2 (de)
BG (2) BG110386A (de)
BR (1) BR0108126A (de)
CA (1) CA2397262C (de)
CZ (1) CZ296685B6 (de)
DE (1) DE60109903T2 (de)
DK (1) DK1257275T3 (de)
EE (1) EE04836B1 (de)
ES (1) ES2240416T3 (de)
FR (1) FR2804604B1 (de)
HU (1) HU225328B1 (de)
IL (1) IL150710A0 (de)
IS (1) IS6450A (de)
MX (1) MXPA02007766A (de)
NO (1) NO324521B1 (de)
NZ (1) NZ519924A (de)
PL (1) PL201685B1 (de)
PT (1) PT1257275E (de)
RS (1) RS50404B (de)
RU (1) RU2257207C2 (de)
SI (1) SI1257275T1 (de)
SK (1) SK284952B6 (de)
TW (1) TWI243677B (de)
UA (1) UA72783C2 (de)
WO (1) WO2001058450A2 (de)
ZA (1) ZA200205317B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
JP2005500690A (ja) 2001-08-13 2005-01-06 ハネウェル・インターナショナル・インコーポレーテッド オーバーレイヤーパターンを使用してウェハに担持された半導体デバイスの電流制御を提供すること
CA2478338A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
JP4459629B2 (ja) 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
US7091216B2 (en) 2002-08-02 2006-08-15 Merck & Co., Inc. Substituted furo[2,3-b]pyridine derivatives
EP1546115A4 (de) 2002-09-27 2010-08-04 Merck Sharp & Dohme Substituierte pyrimidine
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1575901B1 (de) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Substituierte amide
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
EP1633733B1 (de) * 2003-05-20 2011-01-26 The University of Tennessee Research Foundation Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005044785A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
WO2006025069A2 (en) 2004-07-12 2006-03-09 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
BRPI0706623A2 (pt) * 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
AU2007312233B2 (en) * 2006-10-20 2012-09-20 Abbvie B.V. Micellar nanoparticles of chemical substances
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
EP2548874A3 (de) * 2007-06-28 2013-05-15 Intervet International B.V. Substituierte Piperazine als CB1-Antagonisten
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
JPWO2010018856A1 (ja) * 2008-08-13 2012-01-26 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
CN1250220C (zh) 2006-04-12
BG110386A (en) 2009-09-30
HUP0300237A2 (hu) 2003-07-28
PL358221A1 (en) 2004-08-09
DE60109903T2 (de) 2006-02-09
ES2240416T3 (es) 2005-10-16
EP1257275B1 (de) 2005-04-06
NZ519924A (en) 2005-01-28
HK1051140A1 (en) 2003-07-25
SI1257275T1 (en) 2005-10-31
NO20023765L (no) 2002-10-09
US20050187253A1 (en) 2005-08-25
TWI243677B (en) 2005-11-21
RU2002118309A (ru) 2004-02-20
BR0108126A (pt) 2003-01-28
PT1257275E (pt) 2005-07-29
FR2804604B1 (fr) 2005-05-27
RS50404B (sr) 2009-12-31
DE60109903D1 (de) 2005-05-12
CA2397262C (en) 2007-09-11
UA72783C2 (en) 2005-04-15
HU225328B1 (en) 2006-09-28
AU3562001A (en) 2001-08-20
CZ296685B6 (cs) 2006-05-17
BG65856B1 (bg) 2010-03-31
YU59002A (sh) 2005-07-19
IS6450A (is) 2002-06-28
EE200200439A (et) 2003-12-15
DK1257275T3 (da) 2005-08-08
EE04836B1 (et) 2007-06-15
JP2010018622A (ja) 2010-01-28
WO2001058450A2 (fr) 2001-08-16
JP2003522145A (ja) 2003-07-22
SK11292002A3 (sk) 2003-02-04
US6930122B2 (en) 2005-08-16
US20030087933A1 (en) 2003-05-08
CN1406128A (zh) 2003-03-26
ATE292467T1 (de) 2005-04-15
ZA200205317B (en) 2003-09-04
NO20023765D0 (no) 2002-08-08
EP1257275A2 (de) 2002-11-20
MXPA02007766A (es) 2002-10-11
CA2397262A1 (en) 2001-08-16
FR2804604A1 (fr) 2001-08-10
AR028505A1 (es) 2003-05-14
HUP0300237A3 (en) 2003-09-29
RU2257207C2 (ru) 2005-07-27
BG106946A (bg) 2003-05-30
AU781827B2 (en) 2005-06-16
NO324521B1 (no) 2007-11-12
CZ20022698A3 (cs) 2002-11-13
SK284952B6 (sk) 2006-03-02
WO2001058450A3 (fr) 2002-04-25
PL201685B1 (pl) 2009-04-30

Similar Documents

Publication Publication Date Title
SI1257275T1 (en) Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
HUP0301671A3 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
MXPA03000923A (es) Compuestos de carboxamida y su uso como antagonistas de un receptor 11cby humano.
HUP0302044A3 (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
AU2001235691A1 (en) Use of paullone derivatives for making medicines
EP1224173A4 (de) Pyrazol-derivate als cannabinoidrezeptor-antagonisten
IL148593A0 (en) T2r, a novel family of taste receptors
IL146928A0 (en) Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
PT1347760E (pt) Composicoes farmaceuticas de agonista do receptor de nmda
HUP0700039A2 (en) Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation
HUP0302382A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
SI1305319T1 (sl) 4-fenil-piridinski derivati kot receptorski antagonisti nevrokinina-1
HUP0201937A3 (en) Substituted 1,5-dihydropyrrol-2-on derivatives, process for producing them and pharmaceutical compositions containing them having nmda receptor antagonist effect
PL353613A1 (en) Application of oestrogen agonist/antagonist in production of a drug
GB0207104D0 (en) Stable hydrate of a muscarinic receptor antagonist
PL360885A1 (en) 10-aryl-11h-benzo [b]fluorene derivatives and analogs for medicinal use
HUP0300599A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
HUP0302003A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
HUP0201300A3 (en) Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them
GB0011817D0 (en) Antagonists of integrin receptors
PL361805A1 (en) Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
HUP0300694A3 (en) Indole derivatives as mcp-1 receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
PL376866A1 (pl) Nowe antagonistyczne pochodne receptora witronektyny, sposób ich przygotowania, ich zastosowanie jako leków i kompozycje farmaceutyczne je zawierające

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees